Track the Order
info@rxmedilife.comNew Year Sale upto 55% Off
Great medicine with best rxmedilife branded, 100% genuine pharmacy
HERVYCTA PLUS 150MG Injection is a targeted therapy used in the treatment of HER2-positive breast and gastric cancers. It contains Trastuzumab, a monoclonal antibody that specifically targets the HER2 protein, which plays a crucial role in cancer cell growth and proliferation.
Blocks HER2 Receptors – HERVYCTA binds to HER2 receptors on cancer cells, preventing their uncontrolled growth.
Activates the Immune System – Helps the body's immune system recognize and destroy HER2-positive cancer cells.
Prevents Cancer Spread – Reduces tumor size and slows cancer progression.
Patients with HER2-positive breast cancer (early-stage or metastatic).
Patients with HER2-positive gastric cancer (stomach cancer).
Those undergoing chemotherapy or post-surgery treatment.
Given as an intravenous (IV) imbuement in a medical clinic or facility.
First dose: 90-minute infusion, followed by maintenance doses every 1–3 weeks.
Improves survival rates in HER2-positive cancers.
Reduces the risk of cancer recurrence after surgery.
Enhances the effectiveness of chemotherapy.
Well-tolerated with manageable side effects.
Common Side Effects:
Serious Side Effects (Seek Medical Help):
Not recommended for pregnant or breastfeeding women.
Requires heart function monitoring before and during treatment.
Use with alert in patients with previous coronary illness.
HERVYCTA PLUS 150MG Injection is a powerful targeted therapy for HER2-positive breast and gastric cancers. When combined with chemotherapy or surgery, it significantly improves survival rates and reduces the risk of cancer returning. Regular medical supervision is essential to monitor heart health and manage any side effects.
